Show simple item record

dc.contributor.authorMarques-Smith, Patrick
dc.contributor.authorKallerud, Anne Selven
dc.contributor.authorJohansen, Grethe Marie
dc.contributor.authorBoysen, Preben
dc.contributor.authorJacobsen, Anna M.
dc.contributor.authorReitan, Karoline Mosand
dc.contributor.authorHenriksen, Mia Mehlum
dc.contributor.authorLöfgren, Maria
dc.contributor.authorFjordbakk, Cathrine T
dc.date.accessioned2020-11-11T08:52:42Z
dc.date.available2020-11-11T08:52:42Z
dc.date.created2020-06-25T14:01:19Z
dc.date.issued2020
dc.identifier.issn1746-6148
dc.identifier.urihttps://hdl.handle.net/11250/2687266
dc.description.abstractBackground Biologic’ therapies, such as autologous conditioned serum (ACS), are gaining popularity in treating orthopaedic conditions in equine veterinary medicine. Evidence is scarce regarding ACS constituents, and large inter-individual differences in cytokine and growth factor content have been demonstrated. The objective of the current study was to investigate the potential association between cytokine and growth factor content of ACS and clinical effect in harness racehorses with spontaneously occurring low-grade articular lameness. Horses received 3 intra-articular injections of ACS administered at approximately 2-week intervals. Lameness evaluation consisting of a trot-up with subsequent flexions tests was performed at inclusion and approximately 2 weeks after the last treatment (re-evaluation); horses were classified as responders when there was no detectable lameness on trot-up and a minimum of 50% reduction in flexion test scores at re-evaluation. Association between clinical outcome (responders vs. non-responders) and age, lameness grades at inclusion (both initial trot-up and after flexion tests), treatment interval, follow-up time and the ACS content of IL-1Ra, IGF-1 and TGF-β was determined by regression modelling. Results Outcome analysis was available for 19 of 20 included horses; 11 responded to treatment whereas 8 did not. There was considerable inter-individual variability in cytokine/growth factor content of ACS, and in the majority of the horses, the level of IL-10, IL-1β and TNF-α was below the detection limit. In the final multivariate logistic regression model, ACS content of IGF-1 and IL-1Ra was significantly associated with clinical response (P = 0.01 and P = 0.03, respectively). No association with clinical response was found for the other tested variables. Conclusions The therapeutic benefit of ACS may be related to higher levels of IL-1Ra and IGF-1. Our study corroborates previous findings of considerable inter-individual variability of cytokine- and growth factor content in ACS.en_US
dc.language.isoengen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleIs clinical effect of autologous conditioned serum in spontaneously occurring equine articular lameness related to ACS cytokine profile?en_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.volume16en_US
dc.source.journalBMC Veterinary Researchen_US
dc.identifier.doi10.1186/s12917-020-02391-7
dc.identifier.cristin1817143
dc.relation.projectNorges forskningsråd: 272328en_US
dc.source.articlenumber181en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal